Tele: 561.316.3330
Breaking Medical Device News

Friday, October 15, 2021
HomeBIOTECHNOLOGYCOVID-19 Microneedle Vaccine Delivery, to Enhance Efficiency and Reduce Dose In the...

COVID-19 Microneedle Vaccine Delivery, to Enhance Efficiency and Reduce Dose In the Works

Debiotech will be collaborating with vaccine companies, foundations, and public organizations, using its unique DebioJect™ Microneedle, to improve the effectiveness of COVID-19 vaccines by reducing the necessary dose to achieve a sufficient immune response. The news was announced today.

It is already well documented that the immune response induced by intradermal administration of fifth of an intradermal dose for rabies is equivalent to the full dose given intramuscularly. In the case of the influenza vaccine, the same intradermally injected dose has been shown to elicit a superior immune response in the elderly. These micro-needles, therefore, address two key issues related to the current pandemic: faster access to a larger share population with the same vaccine production capacity and better protection of the most vulnerable part of the population.

A recent publication in the Lancet demonstrated the value of the intradermal approach in the case of COVID-19: microneedles were used to deliver a subunit vaccine in a pre-clinical in-vivo animal trial, inducing the production of specific antibodies within 2 weeks from the injection (EBioMedicine, University of Pittsburgh, April 2nd, 2020).

The success of intradermal injections with conventional methods requires experience and skills. This problem no longer exists with the DebioJect™, which can be used without specific training. The CE marked DebioJect™ Microneedle consist of one short (less than 1mm) hollow microneedle, part of a disposable automatic insertion device. It can infuse up to 0.5 milliliters of a liquid formulation in less than five seconds, just like a conventional injection. The microneedles are manufactured using Micro-Electro-Mechanical System (MEMS) techniques which are capable of producing billions of microneedles on a single fully automatized production line.

“We are eager to actively participate to one of the most important challenges of our times, protecting the population against this COVID-19 pandemic by use of all available technologies, vaccines, and drugs,” says Frédéric Neftel, MD, President of DEBIOTECH SA. “We have been already working for many years on innovative intradermal vaccine delivery systems, which could be one way to increase the efficiency of future vaccines while making it available to more patients with the same dose amount.”

“DebioJect™ has already been successfully used on humans in multiple studies and can be produced at a very high scale, thanks to a unique MEMS production process we have been working on for over 10 years,” says Laurent-Dominique Piveteau, Ph.D., MBA INSEAD, CEO of DEBIOTECH. “Our entire team of over 50 Ph.D.’s, engineers and technicians are ready to move into this exciting task to deliver a potentially novel and more efficient vaccine technology to everyone.”

Note: Debiotech is currently offering to collaborate with every company, foundation or organization active in the COVID-19 vaccine testing.

Medical Device News Magazine
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected


Don't Miss

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

Global Healthcare Exchange Announces Acquisition of Explorer Surgical

Explorer Surgical will operate as a wholly-owned subsidiary of GHX.

Arlington Scientific Broadens Product Portfolio and Further Expands its Product Offering Through the acquisition of Non-Mammalian Blocking Buffers

Arlington Scientific, Inc. (ASI) is pleased to announce that it has acquired the non-mammalian blocking buffer product line from Clark McDermith, former owner of...

Laborie Medical Technologies Acquires Pelvalon

Laborie was represented by Piper Sandler (financial advisor) and Simpson Thacher & Bartlett LLP (legal advisor). Pelvalon was represented by J.P. Morgan Securities LLC (financial advisor) and Dorsey & Whitney LLP (legal advisor).

Herculite Products, Inc. Promotes Two Employees to New Roles

Paul Flaherty Chief Strategy Officer and Marco Angelone is being promoted to the role of Chief Financial Officer.

Prof. Joseph Kvedar Added to the Sweetch Advisory Board Member

Prof. Josdeph Kvedar is the current chair of the board at the American Telemedicine Association (ATA), formerly VP of Connected Health at Mass-Gen Brigham, co-chair of the American Medical Association (AMA) Digital Medicine Payment Advisory Group, and author of The Internet of Healthy Things and The New Mobile Age.

Sid Bala Named President of HealthChampion

Sid Bala is the former president and chief executive officer of alligatortek, a custom software applications company that was acquired by HealthChampion in 2020 where he led them for 27 years after he founded the business

Cochlear Announces FDA Approval and Clearance of first-of-its-kind Remote Care Capabilities for Nucleus and Baha Systems

The FDA approval for the cochlear implant solution and FDA clearance for the Baha solution is the first step in commercializing the product offering, anticipated spring 2022, and complement Cochlear's existing Remote Care offerings.

By using this website you agree to accept Medical Device News Magazine Privacy Policy